22:39 on September 8, 2021, Beijing time, OTC market in the United StatesWUHAN GENERAL GP (WUHN.us)The stock changed, and the share price plunged by 7.83%. As of press time, the stock was trading at US $0.700 per share, with a turnover of 1001 shares, a turnover rate of 0.005% and an amplitude of 0.005%.
Recent financial data show that the stock has an operating income of $2362.00.Net profit-$281603.00, earnings per share-$0.010Gross profit419.00 U.S. dollars, with a price-to-earnings ratio of-85.37 times.
In terms of agency rating, there is currently no agency to make "buy, hold, sell" recommendations on the stock.
In the pharmaceutical industry in which WUHAN GENERAL GP shares are located in the US OTC market, the overall decline was 0.59 per cent. Among its related stocksBailigao、Cumberland Pharmaceutical Co., Ltd.、Clever Leaves Holdings IncThe increase is relatively large.Sonoma Pharmaceuticals Inc、Teligent Inc New、Sundial Growers IncRelatively active, with turnover rates of 5.50%, 3.92% and 1.47%, respectively. The related stocks with larger amplitudes areMedavail Holdings Inc、Clever Leaves Holdings Inc C/Wts 18 + 12 * 2025 (To Pur Com)And Sonoma Pharmaceuticals Inc, the amplitudes are 8.48%, 7.94% and 7.90%, respectively.
About WUHAN GENERAL GP in American OTC Market: M2Bio Sciences Inc, formerly known as WUHAN GENERAL GP Group (China) Co., Ltd., is an alternative pharmaceutical company dedicated to the application of emerging technologies and clinical research and health applications of cannabinol (CBD)-based drugs in the human and pet care industries in Canada, the United States, Europe and Australia for cancer, cardiovascular disease, and mental illness. Chronic pain and other diseases. It provides medical-grade CBD products and quality patient care.
(the above content is completed by Money Call, a self-selected intelligent machine writer, and is only used as a reference for users to look at the market, not as a basis for transaction. )